RNF43 is altered in 9.03% of colorectal carcinoma patients with RNF43 Loss present in 0.09% of all colorectal carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RNF43 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

RNF43 is altered in 3.54% of malignant solid tumor patients with RNF43 Loss present in 0.03% of all malignant solid tumor patients [4].

RNF43 Loss is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain RNF43 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [5].

RNF43 is altered in 4.01% of breast carcinoma patients with RNF43 Loss present in 0.04% of all breast carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 6.13% of pancreatic adenocarcinoma patients with RNF43 Loss present in 0.04% of all pancreatic adenocarcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 6.04% of pancreatic carcinoma patients with RNF43 Loss present in 0.04% of all pancreatic carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 2.13% of cervical squamous cell carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 1.08% of esophageal squamous cell carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 1.64% of head and neck carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 1.87% of head and neck squamous cell carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 3.56% of melanoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RNF43 is altered in 0.91% of squamous cell lung carcinoma patients [4].

RNF43 Loss is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].